The genetic background shapes the susceptibility to mitochondrial dysfunction and NASH progression.
Giorgia BenegiamoGiacomo V G von AlvenslebenSandra Rodríguez-LópezLudger J E GoeminneAlexis M BachmannJean-David MorelEllen BroeckxJing Ying MaVinicius S CarreiraSameh A YoussefNabil AzharDermot F ReillyKatharine D'AquinoShannon MullicanMaroun Bou SleimanJohan AuwerxPublished in: The Journal of experimental medicine (2023)
Non-alcoholic steatohepatitis (NASH) is a global health concern without treatment. The challenge in finding effective therapies is due to the lack of good mouse models and the complexity of the disease, characterized by gene-environment interactions. We tested the susceptibility of seven mouse strains to develop NASH. The severity of the clinical phenotypes observed varied widely across strains. PWK/PhJ mice were the most prone to develop hepatic inflammation and the only strain to progress to NASH with extensive fibrosis, while CAST/EiJ mice were completely resistant. Levels of mitochondrial transcripts and proteins as well as mitochondrial function were robustly reduced specifically in the liver of PWK/PhJ mice, suggesting a central role of mitochondrial dysfunction in NASH progression. Importantly, the NASH gene expression profile of PWK/PhJ mice had the highest overlap with the human NASH signature. Our study exposes the limitations of using a single mouse genetic background in metabolic studies and describes a novel NASH mouse model with features of the human NASH.
Keyphrases
- mouse model
- high fat diet induced
- endothelial cells
- genome wide
- global health
- copy number
- escherichia coli
- oxidative stress
- skeletal muscle
- wild type
- insulin resistance
- type diabetes
- liver injury
- drug induced
- dna methylation
- transcription factor
- induced pluripotent stem cells
- combination therapy
- pluripotent stem cells
- liver fibrosis
- replacement therapy